The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Should routine CH screening of donors become standard practice across transplant programs?
In this video, Ibrahim Yakoub-Agha, MD, PhD, University of Lille, Lille, France, discusses the current approach to screening donors and recipients for clonal hematopoiesis (CH), stating that donors should be screened on a case-by-case basis due to the current limited data available. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It’s difficult to answer this question right now because we don’t have enough data. Of course, we are gathering more and more data in the future, but for now, I would say I would continue screening the donor and the recipient. No, the recipient is a routine, but for the donor, base it on a case-by-case basis, not the routine right now. Maybe it can change. If you ask me next year or two years, maybe I will change my opinion, but right now, no...
It’s difficult to answer this question right now because we don’t have enough data. Of course, we are gathering more and more data in the future, but for now, I would say I would continue screening the donor and the recipient. No, the recipient is a routine, but for the donor, base it on a case-by-case basis, not the routine right now. Maybe it can change. If you ask me next year or two years, maybe I will change my opinion, but right now, no.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
